# K220916: iLet® Dosing Decision Software

- Pathway: 510(k) (Traditional)
- Applicant: Beta Bionics, Inc.
- Decided: May 19, 2023 after 415 days
- Product code: QJI (Interoperable Automated Glycemic Controller)
- Device class: 2
- Regulation: 21 CFR 862.1356
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 2 generations back to DEN190034 (2019). 2 ancestors in all.
2 later devices descend from it; 1 cites it directly.
0 of 5 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K200467: Control-IQ Technology, Tandem Diabetes Care, Inc. (2020) Summary page 4.

## Most influential descendants
- K232224: iLet® Dosing Decision Software (2023), 1 descendant of its own
- K262763: iLet Dosing Decision Software (2026), 0 descendants of its own

## Indications for use
The iLet Dosing Decision Software is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) pumps. A self-monitoring of blood glucose (SMBG) meter may also be used for manual input of blood glucose values to continue insulin dosing for a limited period of time when input from the iCGM is temporarily not available. The iLet Dosing Decision Software autonomously determines and commands an increase, decrease, maintenance, or suspension of all basal doses of insulin and autonomously determines and commands correction doses of insulin based on input from an iCGM, and it autonomously determines and commands meal doses of insulin based on meal announcements. iLet Dosing Decision Software is intended for the management of type 1 diabetes mellitus in people 6 years of age or older. iLet Dosing Decision Software is intended for single patient use and requires a prescription.

Source page: https://510kreport.com/device/K220916
Methodology: https://510kreport.com/methodology